Modalis Therapeutics（4883）株式概要モダリス・セラピューティクス・コーポレーションは、重篤な遺伝性疾患患者を治療するための治療薬の研究開発に従事しています。 詳細4883 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析JP市場と比較して、過去 3 か月間の株価の変動が非常に大きい過去5年間で収益は年間14%減少しました。 収益が 100 万ドル未満 ( ¥0 )意味のある時価総額がありません ( ¥3B )+1 さらなるリスクすべてのリスクチェックを見る4883 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW472,181 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA472,181 investors already sharing narrativesYour Fair ValueJP¥Current PriceJP¥33.00該当なし内在価値ディスカウントEst. Revenue$PastFuture-3b569m2016201920222025202620282031Revenue JP¥0.00001Earnings JP¥0.000002AdvancedSet Fair ValueView all narrativesModalis Therapeutics Corporation 競合他社Perseus ProteomicsSymbol: TSE:4882Market cap: JP¥2.6bTransgenic GroupSymbol: TSE:2342Market cap: JP¥3.8bKringle PharmaSymbol: TSE:4884Market cap: JP¥2.5bFunPepSymbol: TSE:4881Market cap: JP¥2.5b価格と性能株価の高値、安値、推移の概要Modalis Therapeutics過去の株価現在の株価JP¥33.0052週高値JP¥97.0052週安値JP¥29.00ベータ0.391ヶ月の変化-2.94%3ヶ月変化-51.47%1年変化-63.33%3年間の変化-77.40%5年間の変化-97.25%IPOからの変化-98.52%最新ニュースお知らせ • Jun 01Modalis Therapeutics Corporation to Report Q2, 2026 Results on Aug 10, 2026Modalis Therapeutics Corporation announced that they will report Q2, 2026 results on Aug 10, 2026お知らせ • May 28Modalis Therapeutics Corporation announced that it expects to receive ¥2.64 million in funding from Evolution Capital Management LLCModalis Therapeutics Corporation has announced a private placement to issue 240,000 19th Series Stock Acquisition Rights Certificates at the price of ¥11 for the gross proceeds of the ¥2,640,000 on May 27, 2026. The transaction involves the returning investor participation of Evo Fund for 240,000 stock acquisition rights. The transaction will happen through third party allocation. The exercise price of the stock acquisition rights will be ¥28 and will have an exercise period from June 15, 2026, to March 15, 2027. The transaction is approved by the board of directors and subject to approval of board of directors for transfer of these stock acquisition rights. The transaction is expected close on June 12, 2026.分析記事 • Apr 29Here's Why We're Watching Modalis Therapeutics' (TSE:4883) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...New Risk • Apr 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 18% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (JP¥4.84b market cap, or US$30.4m).お知らせ • Feb 12Modalis Therapeutics Corporation, Annual General Meeting, Mar 26, 2026Modalis Therapeutics Corporation, Annual General Meeting, Mar 26, 2026.New Risk • Jan 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (JP¥4.87b market cap, or US$31.1m).最新情報をもっと見るRecent updatesお知らせ • Jun 01Modalis Therapeutics Corporation to Report Q2, 2026 Results on Aug 10, 2026Modalis Therapeutics Corporation announced that they will report Q2, 2026 results on Aug 10, 2026お知らせ • May 28Modalis Therapeutics Corporation announced that it expects to receive ¥2.64 million in funding from Evolution Capital Management LLCModalis Therapeutics Corporation has announced a private placement to issue 240,000 19th Series Stock Acquisition Rights Certificates at the price of ¥11 for the gross proceeds of the ¥2,640,000 on May 27, 2026. The transaction involves the returning investor participation of Evo Fund for 240,000 stock acquisition rights. The transaction will happen through third party allocation. The exercise price of the stock acquisition rights will be ¥28 and will have an exercise period from June 15, 2026, to March 15, 2027. The transaction is approved by the board of directors and subject to approval of board of directors for transfer of these stock acquisition rights. The transaction is expected close on June 12, 2026.分析記事 • Apr 29Here's Why We're Watching Modalis Therapeutics' (TSE:4883) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...New Risk • Apr 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 18% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (JP¥4.84b market cap, or US$30.4m).お知らせ • Feb 12Modalis Therapeutics Corporation, Annual General Meeting, Mar 26, 2026Modalis Therapeutics Corporation, Annual General Meeting, Mar 26, 2026.New Risk • Jan 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (JP¥4.87b market cap, or US$31.1m).分析記事 • Dec 19Is Modalis Therapeutics (TSE:4883) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...お知らせ • Dec 03Modalis Therapeutics Corporation to Report Fiscal Year 2025 Results on Feb 12, 2026Modalis Therapeutics Corporation announced that they will report fiscal year 2025 results on Feb 12, 2026お知らせ • Oct 01Modalis Therapeutics Corporation to Report Q3, 2025 Results on Nov 07, 2025Modalis Therapeutics Corporation announced that they will report Q3, 2025 results on Nov 07, 2025お知らせ • Aug 25Modalis Therapeutics Corporation announced that it has received ¥3.072 million in funding from Evolution Capital Management LLCOn August 25, 2025, Modalis Therapeutics Corporation closed the transaction. The exercise price will be of ¥91 and exercise period is from August 26, 2025 to April 27, 2026. The transaction includes participation from returning investor, Evo Fund, a fund managed by Evolution Capital Management LLC.お知らせ • Jun 27Modalis Therapeutics Corporation to Report Q2, 2025 Results on Aug 07, 2025Modalis Therapeutics Corporation announced that they will report Q2, 2025 results on Aug 07, 2025分析記事 • Jun 14We're Not Very Worried About Modalis Therapeutics' (TSE:4883) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • Jun 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 26% per year over the past 5 years. Shareholders have been substantially diluted in the past year (104% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (JP¥7.94b market cap, or US$55.1m).お知らせ • Apr 08Modalis Therapeutics Corporation to Report Q1, 2025 Results on May 08, 2025Modalis Therapeutics Corporation announced that they will report Q1, 2025 results on May 08, 2025分析記事 • Mar 01We Think Modalis Therapeutics (TSE:4883) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...お知らせ • Feb 13Modalis Therapeutics Corporation, Annual General Meeting, Mar 27, 2025Modalis Therapeutics Corporation, Annual General Meeting, Mar 27, 2025.お知らせ • Jan 03Modalis Therapeutics Corporation to Report Fiscal Year 2024 Results on Feb 13, 2025Modalis Therapeutics Corporation announced that they will report fiscal year 2024 results on Feb 13, 2025お知らせ • Sep 28Modalis Therapeutics Corporation to Report Q3, 2024 Results on Nov 07, 2024Modalis Therapeutics Corporation announced that they will report Q3, 2024 results on Nov 07, 2024New Risk • Sep 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 57% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings have declined by 48% per year over the past 5 years. Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (JP¥4.56b market cap, or US$32.4m).New Risk • Jul 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥2.3b free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 54% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (JP¥4.02b market cap, or US$26.0m).お知らせ • Jun 30Modalis Therapeutics Corporation to Report Q2, 2024 Results on Aug 07, 2024Modalis Therapeutics Corporation announced that they will report Q2, 2024 results on Aug 07, 2024お知らせ • May 08Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101Modalis Therapeutics Corporation posted the preprint paper titled "Efficient and durable gene activation by Cas9-mediated epigenome editing in vivo" on bioRxiv. The company reported data demonstrating exceptional durability, robust efficacy and safety in dyW mouse disease model of LAMA2-CMD and in adult and juvenile NHPs. LAMA2-CMD is a severe, early onset congenital muscular dystrophy caused by the absence of the LAMA2 protein. Despite significant advances in gene therapy and the approval of about a dozen therapies, the size of the disease-causing gene of LAMA2-CMD, which exceeds 3,000 amino acids, hinders the conventional gene therapy approach using AAV vectors to deliver the healthy version of the mutated gene. No approved therapies to address the root cause of this condition exist or are in clinical trials. Modalis' proprietary CRISPR-GNDM, is capable of specific modulation of the expression of disease-relevant genes, without introducing double-strand DNA breaks, and the company's MDL-101 is potentially the first-in-class therapeutics to solve the challenge and provide life-changing therapeutics for the patients of LAMA2-CMD.お知らせ • Mar 02Modalis Therapeutics Corporation to Report Q1, 2024 Results on May 08, 2024Modalis Therapeutics Corporation announced that they will report Q1, 2024 results on May 08, 2024New Risk • Feb 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥2.3b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥2.3b free cash flow). Share price has been highly volatile over the past 3 months (8.9% average weekly change). Earnings have declined by 51% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (JP¥3.20b market cap, or US$21.3m).お知らせ • Feb 16Modalis Therapeutics Corporation, Annual General Meeting, Mar 26, 2024Modalis Therapeutics Corporation, Annual General Meeting, Mar 26, 2024.お知らせ • Dec 05Modalis Therapeutics Corporation to Report Fiscal Year 2023 Results on Feb 14, 2024Modalis Therapeutics Corporation announced that they will report fiscal year 2023 results on Feb 14, 2024お知らせ • Nov 09Modalis Therapeutics Corporation announced that it expects to receive ¥505.320864 million in funding from Evolution Capital Management LLCModalis Therapeutics Corporation announced a private placement to issue 78,248 units 12 stock acquisition rights ¥68 per rights for the gross proceeds of ¥5,320,864 and 1st series of unsecured convertible bonds with stock acquisition rights for the gross proceeds of ¥500,000,000; aggregate gross proceeds of ¥505,320,864 on November 7, 2023. The transaction will include participation from new investor Evo Fund, a fund managed by Evolution Capital Management LLC. The transaction has been approved by the shareholders of the company and is expected to close on November 30, 2023. The bonds bear zero coupon rate and matures on December 1, 2025. The bonds are convertible into initial conversion price of ¥136 per share. The rights can be exercised from December 1, 2023 to December 1, 2025 and minimum exercise price is ¥68.New Risk • Nov 08New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥2.3b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥2.3b free cash flow). Share price has been highly volatile over the past 3 months (9.6% average weekly change). Earnings have declined by 56% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (8.4% increase in shares outstanding). Market cap is less than US$100m (JP¥4.07b market cap, or US$27.0m).お知らせ • Sep 13Modalis Therapeutics Corporation announced that it expects to receive ¥18.77952 million in funding from China Silver Asset Management Hong Kong LimitedModalis Therapeutics Corporation announced a private placement it will issue 78,248 12th stock acquisition rights at a price of ¥240 per share of gross proceeds for ¥18,779,520 on September 11, 2023. The transaction included the participation from new investor CS Asia Opportunities Master Fund, a fund managed by China Silver Asset Management Hong Kong Limited issue 11,158,133 shares and owns 26.13% stake. The securities issued through third party allotment. The company held that the transaction was approved at a meeting of the Company's Board of Directors. The transaction is expected to closing on September 27, 2023.New Risk • Sep 12New major risk - Revenue and earnings growthEarnings have declined by 60% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥2.3b free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 60% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (8.4% increase in shares outstanding). Market cap is less than US$100m (JP¥4.74b market cap, or US$32.3m).お知らせ • Aug 27Modalis Therapeutics Corporation to Report Q3, 2023 Results on Nov 07, 2023Modalis Therapeutics Corporation announced that they will report Q3, 2023 results on Nov 07, 2023New Risk • Aug 10New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥2.3b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥2.3b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (JP¥297m net loss in 2 years). Shareholders have been diluted in the past year (8.4% increase in shares outstanding). Market cap is less than US$100m (JP¥4.48b market cap, or US$31.1m).お知らせ • May 28Modalis Therapeutics Corporation to Report Q2, 2023 Results on Aug 07, 2023Modalis Therapeutics Corporation announced that they will report Q2, 2023 results on Aug 07, 2023Breakeven Date Change • Feb 15Forecast breakeven date moved forward to 2023The analyst covering Modalis Therapeutics previously expected the company to break even in 2024. New forecast suggests the company will make a profit of JP¥737.8m in 2023. Earnings growth of 122% is required to achieve expected profit on schedule.お知らせ • Feb 13Modalis Therapeutics Corporation, Annual General Meeting, Mar 28, 2023Modalis Therapeutics Corporation, Annual General Meeting, Mar 28, 2023.Price Target Changed • Dec 16Price target decreased to JP¥1,150Down from JP¥1,350, the current price target is provided by 1 analyst. New target price is 253% above last closing price of JP¥326. Stock is down 50% over the past year. The company is forecast to post a net loss per share of JP¥32.68 next year compared to a net loss per share of JP¥25.67 last year.お知らせ • Dec 06Modalis Therapeutics Corporation to Report Fiscal Year 2022 Results on Feb 13, 2023Modalis Therapeutics Corporation announced that they will report fiscal year 2022 results on Feb 13, 2023Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Aug 28Modalis Therapeutics Corporation to Report Q3, 2022 Results on Nov 07, 2022Modalis Therapeutics Corporation announced that they will report Q3, 2022 results on Nov 07, 2022Price Target Changed • Aug 04Price target increased to JP¥1,450Up from JP¥1,225, the current price target is an average from 2 analysts. New target price is 196% above last closing price of JP¥490. Stock is down 62% over the past year. The company is forecast to post earnings per share of JP¥14.74 next year compared to a net loss per share of JP¥25.67 last year.お知らせ • May 30Modalis Therapeutics Corporation to Report Q2, 2022 Results on Aug 05, 2022Modalis Therapeutics Corporation announced that they will report Q2, 2022 results on Aug 05, 2022Price Target Changed • Apr 27Price target decreased to JP¥1,250Down from JP¥2,500, the current price target is an average from 3 analysts. New target price is 279% above last closing price of JP¥330. Stock is down 82% over the past year. The company is forecast to post a net loss per share of JP¥4.42 next year compared to a net loss per share of JP¥25.67 last year.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Apr 08Modalis Therapeutics Corporation to Report Q1, 2022 Results on May 09, 2022Modalis Therapeutics Corporation announced that they will report Q1, 2022 results on May 09, 2022Price Target Changed • Feb 27Price target decreased to JP¥1,250Down from JP¥2,500, the current price target is an average from 2 analysts. New target price is 289% above last closing price of JP¥321. Stock is down 86% over the past year. The company is forecast to post earnings per share of JP¥31.34 next year compared to a net loss per share of JP¥25.70 last year.Reported Earnings • Feb 16Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: JP¥25.67 loss per share (down from JP¥17.00 loss in FY 2020). Net loss: JP¥738.0m (loss widened 65% from FY 2020). Revenue missed analyst estimates by 100%. Earnings per share (EPS) were also behind analyst expectations. Over the next year, revenue is forecast to grow 178,233%, compared to a 1,669% growth forecast for the pharmaceuticals industry in Japan.お知らせ • Feb 15Modalis Therapeutics Corporation, Annual General Meeting, Mar 29, 2022Modalis Therapeutics Corporation, Annual General Meeting, Mar 29, 2022.Price Target Changed • Feb 03Price target decreased to JP¥2,500Down from JP¥3,600, the current price target is an average from 3 analysts. New target price is 541% above last closing price of JP¥390. Stock is down 84% over the past year. The company is forecast to post earnings per share of JP¥19.58 next year compared to a net loss per share of JP¥17.00 last year.Board Change • Dec 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Apr 06Full year 2020 earnings released: JP¥17.02 loss per share (vs JP¥5.94 profit in FY 2019)Full year 2020 results: Net loss: JP¥448.4m (down 420% from profit in FY 2019).Executive Departure • Apr 03Scientific Founder & Outside Independent Director Osamu Nureki has left the companyOn the 30th of March, Osamu Nureki's tenure in the role of Scientific Founder & Outside Independent Director ended. As of December 2020, Osamu personally held 4.35m shares (JP¥9.6b worth at the time). Osamu is the only executive to leave the company over the last 12 months.お知らせ • Mar 13Modalis Therapeutics Corporation Announces the Retirement of Osamu Nureki as Director, Effective March 30, 2021Modalis Therapeutics Corporation announced that at the conclusion of the Ordinary General Meeting of Shareholders scheduled to be held on March 30, 2021, Dr. Osamu Nureki, Outside Director will retire from his position.Reported Earnings • Feb 14Full year 2020 earnings released: JP¥17.02 loss per share (vs JP¥5.94 profit in FY 2019)Full year 2020 results: Net loss: JP¥448.4m (down 420% from profit in FY 2019).Analyst Estimate Surprise Post Earnings • Feb 14Revenue beats expectationsRevenue exceeded analyst estimates by 0.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 286%, compared to a 444% growth forecast for the Biotechs industry in Japan.お知らせ • Feb 12Modalis Therapeutics Corporation, Annual General Meeting, Mar 30, 2021Modalis Therapeutics Corporation, Annual General Meeting, Mar 30, 2021.Is New 90 Day High Low • Jan 22New 90-day high: JP¥2,966The company is up 12% from its price of JP¥2,650 on 23 October 2020. The Japanese market is up 14% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is JP¥279 per share.お知らせ • Dec 16Modalis Therapeutics Corporation Revises Consolidated Financial Results Forecast for the Fiscal Year Ending December 31, 2020Modalis Therapeutics Corporation revised consolidated Financial Results Forecast for the Fiscal Year Ending December 31, 2020. For the full year the company forecast operating revenue of JPY 342 million compared previous guidance of to JPY 1,100 million or over. Operating income of JPY 420 compared to previous guidance JPY 350 million or more. Profit attributable to owners of parent of JPY 471 compared to previous guidance of JPY 250 or more. Basic earnings per share of JPY 17.89 compared to previous guidance of JPY 9.63 or over. The downward revision is mainly due to the absence of the upfront payment for license of MDL-101, which was projected in the previous financial results forecast. Company have been under discussion with domestic and overseas pharmaceutical companies, including major pharmaceutical companies, but judging from the current progress, the Company has concluded that it will take more time than previously anticipated before gaining the valuable partnership. The Company believes that further negotiations regarding licensing will lead to better conditions and consequently increase corporate value over the mid to long term. The Company aims to secure licensing within 2021. Data from non-human primate studies, which are currently undergoing analysis and expected to be finalized in early 2021, will support negotiations. Consolidated operating income, consolidated ordinary income, and profit attributable to shareholders of the parent have been revised downward due to the decrease in consolidated operating revenue. The Company Group will continue to make concerted efforts to increase corporate value over the medium to long term.Is New 90 Day High Low • Dec 07New 90-day low: JP¥2,355The company is down 23% from its price of JP¥3,040 on 08 September 2020. The Japanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period.お知らせ • Dec 05Modalis Therapeutics Corporation to Report Fiscal Year 2020 Results on Feb 12, 2021Modalis Therapeutics Corporation announced that they will report fiscal year 2020 results at 6:00 AM, GMT Standard Time on Feb 12, 2021お知らせ • Sep 25Modalis Therapeutics Corporation to Report Q3, 2020 Results on Nov 05, 2020Modalis Therapeutics Corporation announced that they will report Q3, 2020 results on Nov 05, 2020お知らせ • Aug 04Modalis Therapeutics Corporation has completed an IPO in the amount of ¥3.24 billion.Modalis Therapeutics Corporation has completed an IPO in the amount of ¥3.24 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,700,000 Price\Range: ¥1200 Discount Per Security: ¥96 Transaction Features: Sponsor Backed Offering株主還元4883JP BiotechsJP 市場7D6.5%9.1%2.2%1Y-63.3%-29.7%35.3%株主還元を見る業界別リターン: 4883過去 1 年間で-29.7 % の収益を上げたJP Biotechs業界を下回りました。リターン対市場: 4883は、過去 1 年間で35.3 % のリターンを上げたJP市場を下回りました。価格変動Is 4883's price volatile compared to industry and market?4883 volatility4883 Average Weekly Movement9.8%Biotechs Industry Average Movement8.0%Market Average Movement4.4%10% most volatile stocks in JP Market9.5%10% least volatile stocks in JP Market2.2%安定した株価: 4883の株価は、 JP市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 4883の weekly volatility ( 10% ) は過去 1 年間安定していますが、依然としてJPの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト201617Haruhiko Moritamodalistx.comモダリス・セラピューティクス・コーポレーションは、重篤な遺伝性疾患患者を治療するための治療薬の研究開発に従事している。同社は、dCas9を組み合わせた独自のエピゲノム編集技術CRISPR-GNDMを用いて遺伝性疾患の治療法を開発している。また、筋疾患、心筋症、中枢神経系疾患に対する様々な治療薬の開発も行っている。同社は以前はEdiGENE Corporationとして知られていたが、2019年8月にModalis Therapeutics Corporationに社名を変更した。モダリス・セラピューティクス株式会社は2016年に法人化され、日本の中央区に本社を置いている。もっと見るModalis Therapeutics Corporation 基礎のまとめModalis Therapeutics の収益と売上を時価総額と比較するとどうか。4883 基礎統計学時価総額JP¥3.21b収益（TTM）-JP¥1.82b売上高(TTM)n/a0.0xP/Sレシオ-1.8xPER（株価収益率4883 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計4883 損益計算書（TTM）収益JP¥0売上原価JP¥0売上総利益JP¥0その他の費用JP¥1.82b収益-JP¥1.82b直近の収益報告Mar 31, 2026次回決算日Aug 10, 2026一株当たり利益（EPS）-18.74グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%4883 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/06 20:38終値2026/08/06 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Modalis Therapeutics Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Akinori UedaGoldman SachsKiyokazu YamazakiIchiyoshi Research Institute Inc.Tomohiro TanakaSMBC NIKKO
お知らせ • Jun 01Modalis Therapeutics Corporation to Report Q2, 2026 Results on Aug 10, 2026Modalis Therapeutics Corporation announced that they will report Q2, 2026 results on Aug 10, 2026
お知らせ • May 28Modalis Therapeutics Corporation announced that it expects to receive ¥2.64 million in funding from Evolution Capital Management LLCModalis Therapeutics Corporation has announced a private placement to issue 240,000 19th Series Stock Acquisition Rights Certificates at the price of ¥11 for the gross proceeds of the ¥2,640,000 on May 27, 2026. The transaction involves the returning investor participation of Evo Fund for 240,000 stock acquisition rights. The transaction will happen through third party allocation. The exercise price of the stock acquisition rights will be ¥28 and will have an exercise period from June 15, 2026, to March 15, 2027. The transaction is approved by the board of directors and subject to approval of board of directors for transfer of these stock acquisition rights. The transaction is expected close on June 12, 2026.
分析記事 • Apr 29Here's Why We're Watching Modalis Therapeutics' (TSE:4883) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
New Risk • Apr 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 18% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (JP¥4.84b market cap, or US$30.4m).
お知らせ • Feb 12Modalis Therapeutics Corporation, Annual General Meeting, Mar 26, 2026Modalis Therapeutics Corporation, Annual General Meeting, Mar 26, 2026.
New Risk • Jan 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (JP¥4.87b market cap, or US$31.1m).
お知らせ • Jun 01Modalis Therapeutics Corporation to Report Q2, 2026 Results on Aug 10, 2026Modalis Therapeutics Corporation announced that they will report Q2, 2026 results on Aug 10, 2026
お知らせ • May 28Modalis Therapeutics Corporation announced that it expects to receive ¥2.64 million in funding from Evolution Capital Management LLCModalis Therapeutics Corporation has announced a private placement to issue 240,000 19th Series Stock Acquisition Rights Certificates at the price of ¥11 for the gross proceeds of the ¥2,640,000 on May 27, 2026. The transaction involves the returning investor participation of Evo Fund for 240,000 stock acquisition rights. The transaction will happen through third party allocation. The exercise price of the stock acquisition rights will be ¥28 and will have an exercise period from June 15, 2026, to March 15, 2027. The transaction is approved by the board of directors and subject to approval of board of directors for transfer of these stock acquisition rights. The transaction is expected close on June 12, 2026.
分析記事 • Apr 29Here's Why We're Watching Modalis Therapeutics' (TSE:4883) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
New Risk • Apr 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 18% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (JP¥4.84b market cap, or US$30.4m).
お知らせ • Feb 12Modalis Therapeutics Corporation, Annual General Meeting, Mar 26, 2026Modalis Therapeutics Corporation, Annual General Meeting, Mar 26, 2026.
New Risk • Jan 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (JP¥4.87b market cap, or US$31.1m).
分析記事 • Dec 19Is Modalis Therapeutics (TSE:4883) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
お知らせ • Dec 03Modalis Therapeutics Corporation to Report Fiscal Year 2025 Results on Feb 12, 2026Modalis Therapeutics Corporation announced that they will report fiscal year 2025 results on Feb 12, 2026
お知らせ • Oct 01Modalis Therapeutics Corporation to Report Q3, 2025 Results on Nov 07, 2025Modalis Therapeutics Corporation announced that they will report Q3, 2025 results on Nov 07, 2025
お知らせ • Aug 25Modalis Therapeutics Corporation announced that it has received ¥3.072 million in funding from Evolution Capital Management LLCOn August 25, 2025, Modalis Therapeutics Corporation closed the transaction. The exercise price will be of ¥91 and exercise period is from August 26, 2025 to April 27, 2026. The transaction includes participation from returning investor, Evo Fund, a fund managed by Evolution Capital Management LLC.
お知らせ • Jun 27Modalis Therapeutics Corporation to Report Q2, 2025 Results on Aug 07, 2025Modalis Therapeutics Corporation announced that they will report Q2, 2025 results on Aug 07, 2025
分析記事 • Jun 14We're Not Very Worried About Modalis Therapeutics' (TSE:4883) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • Jun 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 26% per year over the past 5 years. Shareholders have been substantially diluted in the past year (104% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (JP¥7.94b market cap, or US$55.1m).
お知らせ • Apr 08Modalis Therapeutics Corporation to Report Q1, 2025 Results on May 08, 2025Modalis Therapeutics Corporation announced that they will report Q1, 2025 results on May 08, 2025
分析記事 • Mar 01We Think Modalis Therapeutics (TSE:4883) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
お知らせ • Feb 13Modalis Therapeutics Corporation, Annual General Meeting, Mar 27, 2025Modalis Therapeutics Corporation, Annual General Meeting, Mar 27, 2025.
お知らせ • Jan 03Modalis Therapeutics Corporation to Report Fiscal Year 2024 Results on Feb 13, 2025Modalis Therapeutics Corporation announced that they will report fiscal year 2024 results on Feb 13, 2025
お知らせ • Sep 28Modalis Therapeutics Corporation to Report Q3, 2024 Results on Nov 07, 2024Modalis Therapeutics Corporation announced that they will report Q3, 2024 results on Nov 07, 2024
New Risk • Sep 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 57% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings have declined by 48% per year over the past 5 years. Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (JP¥4.56b market cap, or US$32.4m).
New Risk • Jul 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥2.3b free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 54% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (JP¥4.02b market cap, or US$26.0m).
お知らせ • Jun 30Modalis Therapeutics Corporation to Report Q2, 2024 Results on Aug 07, 2024Modalis Therapeutics Corporation announced that they will report Q2, 2024 results on Aug 07, 2024
お知らせ • May 08Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101Modalis Therapeutics Corporation posted the preprint paper titled "Efficient and durable gene activation by Cas9-mediated epigenome editing in vivo" on bioRxiv. The company reported data demonstrating exceptional durability, robust efficacy and safety in dyW mouse disease model of LAMA2-CMD and in adult and juvenile NHPs. LAMA2-CMD is a severe, early onset congenital muscular dystrophy caused by the absence of the LAMA2 protein. Despite significant advances in gene therapy and the approval of about a dozen therapies, the size of the disease-causing gene of LAMA2-CMD, which exceeds 3,000 amino acids, hinders the conventional gene therapy approach using AAV vectors to deliver the healthy version of the mutated gene. No approved therapies to address the root cause of this condition exist or are in clinical trials. Modalis' proprietary CRISPR-GNDM, is capable of specific modulation of the expression of disease-relevant genes, without introducing double-strand DNA breaks, and the company's MDL-101 is potentially the first-in-class therapeutics to solve the challenge and provide life-changing therapeutics for the patients of LAMA2-CMD.
お知らせ • Mar 02Modalis Therapeutics Corporation to Report Q1, 2024 Results on May 08, 2024Modalis Therapeutics Corporation announced that they will report Q1, 2024 results on May 08, 2024
New Risk • Feb 17New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥2.3b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥2.3b free cash flow). Share price has been highly volatile over the past 3 months (8.9% average weekly change). Earnings have declined by 51% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (JP¥3.20b market cap, or US$21.3m).
お知らせ • Feb 16Modalis Therapeutics Corporation, Annual General Meeting, Mar 26, 2024Modalis Therapeutics Corporation, Annual General Meeting, Mar 26, 2024.
お知らせ • Dec 05Modalis Therapeutics Corporation to Report Fiscal Year 2023 Results on Feb 14, 2024Modalis Therapeutics Corporation announced that they will report fiscal year 2023 results on Feb 14, 2024
お知らせ • Nov 09Modalis Therapeutics Corporation announced that it expects to receive ¥505.320864 million in funding from Evolution Capital Management LLCModalis Therapeutics Corporation announced a private placement to issue 78,248 units 12 stock acquisition rights ¥68 per rights for the gross proceeds of ¥5,320,864 and 1st series of unsecured convertible bonds with stock acquisition rights for the gross proceeds of ¥500,000,000; aggregate gross proceeds of ¥505,320,864 on November 7, 2023. The transaction will include participation from new investor Evo Fund, a fund managed by Evolution Capital Management LLC. The transaction has been approved by the shareholders of the company and is expected to close on November 30, 2023. The bonds bear zero coupon rate and matures on December 1, 2025. The bonds are convertible into initial conversion price of ¥136 per share. The rights can be exercised from December 1, 2023 to December 1, 2025 and minimum exercise price is ¥68.
New Risk • Nov 08New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥2.3b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥2.3b free cash flow). Share price has been highly volatile over the past 3 months (9.6% average weekly change). Earnings have declined by 56% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (8.4% increase in shares outstanding). Market cap is less than US$100m (JP¥4.07b market cap, or US$27.0m).
お知らせ • Sep 13Modalis Therapeutics Corporation announced that it expects to receive ¥18.77952 million in funding from China Silver Asset Management Hong Kong LimitedModalis Therapeutics Corporation announced a private placement it will issue 78,248 12th stock acquisition rights at a price of ¥240 per share of gross proceeds for ¥18,779,520 on September 11, 2023. The transaction included the participation from new investor CS Asia Opportunities Master Fund, a fund managed by China Silver Asset Management Hong Kong Limited issue 11,158,133 shares and owns 26.13% stake. The securities issued through third party allotment. The company held that the transaction was approved at a meeting of the Company's Board of Directors. The transaction is expected to closing on September 27, 2023.
New Risk • Sep 12New major risk - Revenue and earnings growthEarnings have declined by 60% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥2.3b free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 60% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (8.4% increase in shares outstanding). Market cap is less than US$100m (JP¥4.74b market cap, or US$32.3m).
お知らせ • Aug 27Modalis Therapeutics Corporation to Report Q3, 2023 Results on Nov 07, 2023Modalis Therapeutics Corporation announced that they will report Q3, 2023 results on Nov 07, 2023
New Risk • Aug 10New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥2.3b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥2.3b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (JP¥297m net loss in 2 years). Shareholders have been diluted in the past year (8.4% increase in shares outstanding). Market cap is less than US$100m (JP¥4.48b market cap, or US$31.1m).
お知らせ • May 28Modalis Therapeutics Corporation to Report Q2, 2023 Results on Aug 07, 2023Modalis Therapeutics Corporation announced that they will report Q2, 2023 results on Aug 07, 2023
Breakeven Date Change • Feb 15Forecast breakeven date moved forward to 2023The analyst covering Modalis Therapeutics previously expected the company to break even in 2024. New forecast suggests the company will make a profit of JP¥737.8m in 2023. Earnings growth of 122% is required to achieve expected profit on schedule.
お知らせ • Feb 13Modalis Therapeutics Corporation, Annual General Meeting, Mar 28, 2023Modalis Therapeutics Corporation, Annual General Meeting, Mar 28, 2023.
Price Target Changed • Dec 16Price target decreased to JP¥1,150Down from JP¥1,350, the current price target is provided by 1 analyst. New target price is 253% above last closing price of JP¥326. Stock is down 50% over the past year. The company is forecast to post a net loss per share of JP¥32.68 next year compared to a net loss per share of JP¥25.67 last year.
お知らせ • Dec 06Modalis Therapeutics Corporation to Report Fiscal Year 2022 Results on Feb 13, 2023Modalis Therapeutics Corporation announced that they will report fiscal year 2022 results on Feb 13, 2023
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Aug 28Modalis Therapeutics Corporation to Report Q3, 2022 Results on Nov 07, 2022Modalis Therapeutics Corporation announced that they will report Q3, 2022 results on Nov 07, 2022
Price Target Changed • Aug 04Price target increased to JP¥1,450Up from JP¥1,225, the current price target is an average from 2 analysts. New target price is 196% above last closing price of JP¥490. Stock is down 62% over the past year. The company is forecast to post earnings per share of JP¥14.74 next year compared to a net loss per share of JP¥25.67 last year.
お知らせ • May 30Modalis Therapeutics Corporation to Report Q2, 2022 Results on Aug 05, 2022Modalis Therapeutics Corporation announced that they will report Q2, 2022 results on Aug 05, 2022
Price Target Changed • Apr 27Price target decreased to JP¥1,250Down from JP¥2,500, the current price target is an average from 3 analysts. New target price is 279% above last closing price of JP¥330. Stock is down 82% over the past year. The company is forecast to post a net loss per share of JP¥4.42 next year compared to a net loss per share of JP¥25.67 last year.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Apr 08Modalis Therapeutics Corporation to Report Q1, 2022 Results on May 09, 2022Modalis Therapeutics Corporation announced that they will report Q1, 2022 results on May 09, 2022
Price Target Changed • Feb 27Price target decreased to JP¥1,250Down from JP¥2,500, the current price target is an average from 2 analysts. New target price is 289% above last closing price of JP¥321. Stock is down 86% over the past year. The company is forecast to post earnings per share of JP¥31.34 next year compared to a net loss per share of JP¥25.70 last year.
Reported Earnings • Feb 16Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: JP¥25.67 loss per share (down from JP¥17.00 loss in FY 2020). Net loss: JP¥738.0m (loss widened 65% from FY 2020). Revenue missed analyst estimates by 100%. Earnings per share (EPS) were also behind analyst expectations. Over the next year, revenue is forecast to grow 178,233%, compared to a 1,669% growth forecast for the pharmaceuticals industry in Japan.
お知らせ • Feb 15Modalis Therapeutics Corporation, Annual General Meeting, Mar 29, 2022Modalis Therapeutics Corporation, Annual General Meeting, Mar 29, 2022.
Price Target Changed • Feb 03Price target decreased to JP¥2,500Down from JP¥3,600, the current price target is an average from 3 analysts. New target price is 541% above last closing price of JP¥390. Stock is down 84% over the past year. The company is forecast to post earnings per share of JP¥19.58 next year compared to a net loss per share of JP¥17.00 last year.
Board Change • Dec 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Apr 06Full year 2020 earnings released: JP¥17.02 loss per share (vs JP¥5.94 profit in FY 2019)Full year 2020 results: Net loss: JP¥448.4m (down 420% from profit in FY 2019).
Executive Departure • Apr 03Scientific Founder & Outside Independent Director Osamu Nureki has left the companyOn the 30th of March, Osamu Nureki's tenure in the role of Scientific Founder & Outside Independent Director ended. As of December 2020, Osamu personally held 4.35m shares (JP¥9.6b worth at the time). Osamu is the only executive to leave the company over the last 12 months.
お知らせ • Mar 13Modalis Therapeutics Corporation Announces the Retirement of Osamu Nureki as Director, Effective March 30, 2021Modalis Therapeutics Corporation announced that at the conclusion of the Ordinary General Meeting of Shareholders scheduled to be held on March 30, 2021, Dr. Osamu Nureki, Outside Director will retire from his position.
Reported Earnings • Feb 14Full year 2020 earnings released: JP¥17.02 loss per share (vs JP¥5.94 profit in FY 2019)Full year 2020 results: Net loss: JP¥448.4m (down 420% from profit in FY 2019).
Analyst Estimate Surprise Post Earnings • Feb 14Revenue beats expectationsRevenue exceeded analyst estimates by 0.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 286%, compared to a 444% growth forecast for the Biotechs industry in Japan.
お知らせ • Feb 12Modalis Therapeutics Corporation, Annual General Meeting, Mar 30, 2021Modalis Therapeutics Corporation, Annual General Meeting, Mar 30, 2021.
Is New 90 Day High Low • Jan 22New 90-day high: JP¥2,966The company is up 12% from its price of JP¥2,650 on 23 October 2020. The Japanese market is up 14% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is JP¥279 per share.
お知らせ • Dec 16Modalis Therapeutics Corporation Revises Consolidated Financial Results Forecast for the Fiscal Year Ending December 31, 2020Modalis Therapeutics Corporation revised consolidated Financial Results Forecast for the Fiscal Year Ending December 31, 2020. For the full year the company forecast operating revenue of JPY 342 million compared previous guidance of to JPY 1,100 million or over. Operating income of JPY 420 compared to previous guidance JPY 350 million or more. Profit attributable to owners of parent of JPY 471 compared to previous guidance of JPY 250 or more. Basic earnings per share of JPY 17.89 compared to previous guidance of JPY 9.63 or over. The downward revision is mainly due to the absence of the upfront payment for license of MDL-101, which was projected in the previous financial results forecast. Company have been under discussion with domestic and overseas pharmaceutical companies, including major pharmaceutical companies, but judging from the current progress, the Company has concluded that it will take more time than previously anticipated before gaining the valuable partnership. The Company believes that further negotiations regarding licensing will lead to better conditions and consequently increase corporate value over the mid to long term. The Company aims to secure licensing within 2021. Data from non-human primate studies, which are currently undergoing analysis and expected to be finalized in early 2021, will support negotiations. Consolidated operating income, consolidated ordinary income, and profit attributable to shareholders of the parent have been revised downward due to the decrease in consolidated operating revenue. The Company Group will continue to make concerted efforts to increase corporate value over the medium to long term.
Is New 90 Day High Low • Dec 07New 90-day low: JP¥2,355The company is down 23% from its price of JP¥3,040 on 08 September 2020. The Japanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period.
お知らせ • Dec 05Modalis Therapeutics Corporation to Report Fiscal Year 2020 Results on Feb 12, 2021Modalis Therapeutics Corporation announced that they will report fiscal year 2020 results at 6:00 AM, GMT Standard Time on Feb 12, 2021
お知らせ • Sep 25Modalis Therapeutics Corporation to Report Q3, 2020 Results on Nov 05, 2020Modalis Therapeutics Corporation announced that they will report Q3, 2020 results on Nov 05, 2020
お知らせ • Aug 04Modalis Therapeutics Corporation has completed an IPO in the amount of ¥3.24 billion.Modalis Therapeutics Corporation has completed an IPO in the amount of ¥3.24 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,700,000 Price\Range: ¥1200 Discount Per Security: ¥96 Transaction Features: Sponsor Backed Offering
